Pfizer Delves Deeper In Generics Partnership With Strides Arcolab
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Pfizer has further expanded its generic drug portfolio by signing two more license and supply agreements with Strides Arcolab, just four months after Pfizer partnered with the Bangalore-based drug manufacturer to bring generic injectable and oral drugs to the U.S. market
You may also be interested in...
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]
With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market
MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro